When making changes to our diabetes management we sometimes see changes in our total insulin consumption. And it’s easy to jump to conclusions regarding cause and effect. Whether it’s a new insulin, a different diet, a new adjunctive treatment, changes to exercise and body composition, or whatever. It’s easy for example to look at the …
I was recently discussing with others their occasional issue of noticing “stinging” from Fiasp and Lyumjev insulins. Curious, I looked at a block of 7 of my recent days, and counted the boluses the system delivered. In that time there were 639 boluses, which is an average of 91 per day. Overall I do seem …
An announcement from JDRF this morning gave us the news I’d been hoping for: Come the 1st of October (only a few weeks away) Fiasp Penfills will become available via PBS scripts. This is the outcome I had been expecting/hoping for based on scuttlebutt. Prescriptions will come with 1 repeat. Each fill of the script …
I wrote recently about re-usable pens (which I much prefer over the disposables). For years in Australia Novo Nordisk has provided two pens to use with their Penfill cartridges: NovoPen 4: 1U increments up to 60U/dose. NovoPen Echo: has memory of last dose size and time, 0.5U increments up to 30U. Of course, the older NovoPen …
I’ve reported previously about my experiences with insulin timings, including what happens when we go off-label and blend Humalog U100 with Lyumjev U100. I’ve now done another phase of experimentation, with a new data point. And some analysis of why these results might come about. I’ll first rewind a bit and explain that Humalog / …
The 2023 Fiasp supply dramas are entering a new phase. We have an opportunity to contribute to the process in the next week. Scroll on and you’ll find details. But first, some background. Or jump ahead if you’re in a hurry…. History recap In June 2019 Fiasp was added to the Australian Pharmaceutical Benefits Scheme …